- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 223/18 - DibenzazepinesHydrogenated dibenzazepines
Patent holdings for IPC class C07D 223/18
Total number of patents in this class: 43
10-year publication summary
|
3
|
4
|
1
|
1
|
0
|
3
|
1
|
0
|
0
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4742 |
3 |
| F. Hoffmann-La Roche AG | 7837 |
3 |
| Samsung Display Co., Ltd. | 38627 |
2 |
| Sumitomo Chemical Company, Limited | 9016 |
2 |
| Rohm and Haas Electronic Materials Korea Ltd. | 332 |
2 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3304 |
2 |
| Vandria SA | 17 |
2 |
| Contineum Therapeutics, Inc. | 23 |
2 |
| Board of Regents, The University of Texas System | 6107 |
1 |
| University of Southern California | 2132 |
1 |
| University of South Florida | 1876 |
1 |
| Aarhus Universitet | 449 |
1 |
| Cnrs | 95 |
1 |
| Dana-Farber Cancer Institute, Inc. | 2664 |
1 |
| Domain Therapeutics | 60 |
1 |
| Guangzhou Kingmed Center for Clinical Laboratory | 16 |
1 |
| Hamari Chemicals, Ltd. | 33 |
1 |
| Hetero Research Foundation | 172 |
1 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3335 |
1 |
| Nagase & Co., Ltd. | 235 |
1 |
| Other owners | 13 |